

## Freedom of Information Act Disclosure log - Reply Extract

<b>File reference</b>	W22FOI168
<b>Key words</b>	Medicines Cancer, melanoma Dabrafenib + Trametinib
<b>Date of release</b>	22 <sup>nd</sup> July 2022
<b>Attachments</b>	No

You asked

Please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.

A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:

i) **Metastatic Melanoma**

University Hospitals Plymouth NHS Trust does not hold this information. The Trust holds total drug usage data but not by indication.

ii) **Adjuvant Melanoma**

10

iii) **BRAF mutated Lung Cancer**

University Hospitals Plymouth NHS Trust does not hold this information. The Trust holds total drug usage data but not by indication.

### Legal notes

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

**Attachments included:** No